Skip to main content

Table 1 Baseline patient- and disease characteristics by treatment strategy

From: Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

  All patients (N=213) Azacitidine (N=26) Intensive chemotherapy (N=90) BSC (N=97) P-value
Overall Aza vs IC
Age       
 Median (range) 68 (60–96) 70 (60–81) 66 (60–74) 71 (60–96) <0.001 <0.001
 ≥ 70 years 80 (38%) 14 (54%) 10 (11%) 56 (58%) <0.001 <0.001
Sex      0.48 0.27
 Male 119 (56%) 17 (65%) 47 (52%) 55 (57%)
Performance score      <0.001 0.002
 ≥ 2 121 (59%) 5 (19%) 47 (54%) 69 (75%)
HCT-comorbidity index      <0.001 0.029
 Low (0) 98 (46%) 9 (35%) 57 (63%) 32 (33%)
 Intermediate (1–2) 66 (31%) 8 (31%) 18 (20%) 40 (41%)
 High (> 2) 49 (23%) 9 (35%) 15 (17%) 25 (26%)
AML FAB classification      0.27 0.28
 M0/M1 41 (20%) 4 (17%) 21 (21%) 16 (19%)
 M2 87 (42%) 8 (33%) 40 (40%) 39 (47%)
 M4/M5 51 (25%) 11 (46%) 22 (22%) 18 (22%)
 M6/M7 13 (6%) 1 (4%) 4 (4%) 8 (10%)
AML type      0.089 0.056
De novo 139 (65%) 13 (50%) 65 (72%) 61 (63%)
 Secondary 74 (35%) 13 (50%) 25 (28%) 36 (37%)
Bone marrow blasts       
 Median (range) 45 (16–100) 27 (20–88) 52 (20–100) 47 (16–93) <0.001 <0.001
 ≥ 30% 135 (70%) 11 (42%) 67 (77%) 57 (72%) 0.003 0.001
WBC       
 Median (range) 5 (0–360) 3 (0–15) 5 (1–236) 7 (1–360) 0.13 <0.001
 ≥ 15 × 109/l 65 (31%) 0 (0%) 31 (34%) 34 (35%) 0.002 <0.001
LDH       
 Median (range) 324 (116–4835) 259 (136–1133) 340 (134–2664) 332 (116–4835) 0.15 0.092
 > 600 U/l 49 (23%) 2 (8%) 21 (23%) 26 (27%) 0.13 0.15
Cytogenetic risk      0.003 0.48
 Favourable 8 (4%) 0 (0%) 4 (4%) 4 (4%)
 Intermediate 135 (63%) 18 (69%) 62 (69%) 55 (57%)
 Unfavourable 47 (22%) 8 (31%) 21 (23%) 18 (19%)
 Not available 23 (11%) 0 (0%) 3 (3%) 20 (21%)
Molecular markers      0.27 0.45
NPMc+/ITD- 13 (7%) 1 (4%) 9 (11%) 3 (4%)
 Others 163 (93%) 23 (96%) 75 (89%) 65 (96%)
  1. Patients with promyelocytic leukaemia (N = 14) were excluded from this analysis. Abbreviations: BSC, best supportive care only; Aza vs IC, azacitidine versus intensive chemotherapy; HCT, hematopoietic cell transplantation; AML, acute myeloid leukaemia; BM, bone marrow; WBC, white blood cell count; LDH, lactate dehydrogenase; NPMc+/ITD-, cytoplasmic NPM1 without FLT3 internal tandem duplication. Results are reported as N (%) unless otherwise indicated.